Treatment options for small cell lung cancer

Current Oncology Reports

Volumn 6, Issue 4, 2004, Pages 268-271

  Wolf, Todd ^a   Gillenwater, Heidi H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; MARIMASTAT; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; VINCRISTINE;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG TARGETING; ESOPHAGITIS; HUMAN; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; MEDICAL DECISION MAKING; META ANALYSIS; MUSCULOSKELETAL DISEASE; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 5444271968     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0034-1     Document Type: Review

References (19)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics 2004. CA Cancer J Clin 2004, 54:8-29.
2. Page NC, Read WL, Tierney RM, et al.: The epidemiology of small cell cancer [abstract]. Proc ASCO 2002, 21:305a.
3. Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
4. Bonner JA, Sloan JA, Shanahan TG, et al.: Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999, 340:2681-2691.
5. Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002, 20:3054-3060.
6. Fried DB, Morris DE, Hensing TA, et al.: A meta-analysis evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys 2003, 57(Suppl):S139-S140.
7. Videtic GMM, Stitt LW, Dar AR, et al.: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small cell lung cancer is associated with decreased survival. J Clin Oncol 2003, 21:1544-1549.
8. Schiller JH, Kim KM, Hutson P, et al.: Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996, 14:2345-2352.
9. Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10: 225-1229.
10. Noda K, Nishiwaki Y, Kawara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002, 346:85-91.
11. Shepherd FA, Giaccone G, Seymour L, et al.: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20:4434-4439.
12. Potti A, Moazzam N, Ramar K, et al.: CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003, 14:894-897.
13. Krystal GW, Honsawek S, Litz J, et al.: The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth. Clin Cancer Res 2000, 6:19-26.
14. Soria JC, Johnson BE, LeChevalier T: Imatinib in small cell lung cancer. Lung Cancer 2003, 41:S49-53.
15. Betrand R, O'Connor R, Kerrigan D, et al.: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992, 28A:743-748.
16. Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E759: a phase III trial of the ECOG. J Clin Oncol 2001, 19:2114-2122.
17. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991, 9:499-508.
18. Ardizzoni A, Tjan-Heijnen V, Postmus PE, et al.: Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923. J Clin Oncol 2002, 20:3947-3955.
19. Quero Blanco C, Lopez-Picazo JM, Boan J, et al.: Initial staging of small-cell lung cancer(SCLC) patients with 18FDG-PET and conventional imaging techniques [abstract]. Proc ASCO 2003, 22:2618.